Literature DB >> 21222293

Predictors of outcome following Gamma Knife surgery for acromegaly.

Tak Lap Poon1, Samuel Cheong Lun Leung, Christopher Yee Fat Poon, Chung Ping Yu.   

Abstract

OBJECT: Gamma Knife surgery (GKS) is gaining popularity in the treatment of patients with acromegaly after transsphenoidal tumor excision. In this paper, the authors examine the efficacy of GKS and predictors for biochemical remission.
METHODS: The authors retrospectively reviewed data spanning the period 1997–2008 in their hospital Gamma Knife statistics database. Forty patients with a mean age of 64 years (range 19–73 years) underwent GKS for acromegaly during that period. Transsphenoidal subtotal tumor excision had been performed prior to GKS in all these patients, except for 3 deemed to be at high surgical risk. All GKS treatment plans were formulated by the same team that performed the microsurgical procedures. Biochemical remission was defined as a growth hormone (GH) level <2 ng/ml and an insulin-like growth factor–I level that was considered normal with reference to the patient's age and sex. The mean follow-up period after radiosurgery was 73.8 months (range 12–132 months).
RESULTS: Three patients died during the study period of causes unrelated to surgery or GKS. Twenty-nine patients (72.5%) underwent 1 radiosurgery session, and 11 patients (27.5%) required 2 radiosurgery sessions. Among the patients who underwent 1 radiosurgery session, excellent responses (76%–100% reductions in tumor size, GH level, and insulin-like growth factor–I level) were observed in 18 (62%; p < 0.0001), 20 (69%; p < 0.0001), and 5 patients (17%; p = 0.21), respectively. Tumors < 1 cm³ and those with no evidence of cavernous sinus extension were statistically significantly related to a good response in tumor size reduction (p = 0.029 and p = 0.0016, respectively). Subgroup analyses were performed in patients who attained biochemical remission in GH levels; the subgroups included patient sex, patient age, target volume, isodose volume, prescribed dose and isodose, pre-GKS GH level, and evidence of cavernous sinus extension. Only male sex was found to be a statistically significant predictor of good hormone regulation (p = 0.0124). The presence of a cavernous sinus extension was the statistically significant predictor of poor hormone control (p = 0.0011) in our study.
CONCLUSIONS: Subtotal tumor excision followed by GKS was an effective treatment for acromegaly. Tumors < 1 cm³ and those with no evidence of cavernous sinus extension responded well to treatment. Male sex and absence of cavernous sinus involvement can be regarded as predictors of biochemical remission. (DOI: 10.3171/2010.7.GKS10

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21222293

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

1.  Gamma knife radiosurgery for clinically persistent acromegaly.

Authors:  Xiaomin Liu; Hideyuki Kano; Douglas Kondziolka; Kyung-Jae Park; Aditya Iyer; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2012-04-26       Impact factor: 4.130

Review 2.  Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy.

Authors:  Dale Ding; Robert M Starke; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-05       Impact factor: 4.130

Review 3.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Target delineation and optimal radiosurgical dose for pituitary tumors.

Authors:  Giuseppe Minniti; Mattia Falchetto Osti; Maximillian Niyazi
Journal:  Radiat Oncol       Date:  2016-10-11       Impact factor: 3.481

Review 5.  Cranial stereotactic radiosurgery: current status of the initial paradigm shifter.

Authors:  Jason P Sheehan; Chun-Po Yen; Cheng-Chia Lee; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

6.  Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery.

Authors:  Mohana Rao Patibandla; Zhiyuan Xu; Jason P Sheehan
Journal:  J Neurooncol       Date:  2018-02-07       Impact factor: 4.130

7.  Stereotactic radiosurgery in pituitary adenomas: long-term single institution experience and role of the hypothalamic-pituitary axis.

Authors:  Kita Sallabanda; Sergey Usychkin; Fernando Puebla; José C Bustos; José A Gutiérrez-Diaz; Carmen Peraza; César Beltrán; Hugo Marsiglia; José Samblás
Journal:  J Radiosurg SBRT       Date:  2011

Review 8.  Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy.

Authors:  Dale Ding; Chun-Po Yen; Robert M Starke; Cheng-Chia Lee; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-08-14       Impact factor: 4.130

9.  Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.

Authors:  Caroline Sievers; Dorothee M Baur; Anja Schwanke; Michael Buchfelder; Michael Droste; Klaus Mann; Günter K Stalla
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

10.  Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas.

Authors:  Won Kim; Claire Clelland; Isaac Yang; Nader Pouratian
Journal:  Surg Neurol Int       Date:  2012-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.